Systemic Administration of Proteoglycan Protects BALB/c Retired Breeder Mice from Experimental Arthritis

Autor(es):Mostrar menos -

Watanabe Ishikawa, Larissa Lumi ; Colavite, Priscila Maria ; de Campos Fraga-Silva, Thais Fernanda ; Nishiyama Mimura, Luiza Ayumi ; Donega Franca, Thais Graziela ; Goncalves Zorzella-Pezavento, Sofia Fernanda ; Chiuso-Minicucci, Fernanda ; Doddi Marcolino, Larissa ; Marques, Camila ; Valerio Ikoma, Maura Rosane ; Sartori, Alexandrina

• Tipo de documento: Artigo Científico
• Fonte: JOURNAL OF IMMUNOLOGY RESEARCH; v. 2016, p. 11-pg., 2016-01-01.

Resumo

This study was undertaken to evaluate the prophylactic potential of proteoglycan (PG) administration in experimental arthritis. Female BALB/c retired breeder mice received two (2xPG50 and 2xPG100 groups) or three (3xPG50 group) intraperitoneal doses of bovine PG (50 mu g or 100 mu g) every three days. A week later the animals were submitted to arthritis induction by immunization with three i.p. doses of bovine PG associated with dimethyldioctadecylammonium bromide adjuvant at intervals of 21 days. Disease severity was daily assessed after the third dose by score evaluation. The 3xPG50 group showed significant reduction in prevalence and clinical scores. This protective effect was associated with lower production of IFN-gamma and IL-17 and increased production of IL-5 and IL-10 by spleen cells restimulated in vitro with PG. Even though previous PG administration restrained dendritic cellsmaturation this procedure did not alter the frequency of regulatory Foxp3(+) T cells. Lower TNF-alpha and IL-6 levels and higher expression of ROR-gamma and GATA-3 were detected in the paws of protected animals. A delayed-type hypersensitivity reaction confirmed specific tolerance induction. Taken together, these results indicate that previous PG inoculation determines a specific tolerogenic effect that is able to decrease severity of subsequently induced arthritis. (AU)

• Processo FAPESP: 11/17325-4 - Estratégias imunomoduladoras na artrite experimental baseadas na indução de tolerância específica por vitamina D3 e rapamicina
• Beneficiário: Alexandrina Sartori
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 10/20470-3 - Estratégias tolerogênicas antígeno-específicas visando profilaxia e terapia na artrite autoimune experimental.
• Beneficiário: Larissa Lumi Watanabe Ishikawa
• Modalidade de apoio: Bolsas no Brasil - Doutorado